Thromboembolism
Thromboembolism refers to the obstruction of a blood vessel by a blood clot (thrombus) that has dislodged from its site of formation and traveled through the bloodstream. Venous thromboembolism (VTE), which encompasses conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and complex disease[1]; [2]. It affects approximately two individuals out of every thousand annually [2].
The formation of blood clots is a complex biological process involving various pathways, including anticoagulant, procoagulant, fibrinolytic, and innate immunity systems [3]. Both environmental and genetic factors contribute to the risk of VTE [1]. The heritability of VTE is estimated to be around 30% [1], with familial risks being well-documented [4]; [5]; [6]. Genome-wide association studies (GWAS) have been instrumental in identifying specific genetic risk loci and revealing genetic overlaps with arterial vascular diseases [1]; [7]; [2]; [8].
Thromboembolism carries significant clinical consequences, including a mortality rate of 10% for venous thrombosis[2]. Patients who experience a venous thrombosis event face an annual recurrence risk of approximately 6% [2], and about 25% develop post-thrombotic syndrome within five years [2]. Risk factors include malignancy, certain medical treatments like steroids and asparaginase, immobilization, and the use of central venous lines [9]. Obesity has also been implicated as a causal risk factor[10]. From a public health perspective, VTE is a substantial concern [11], with significant economic costs [2]. For example, in England, an estimated 25,000 individuals die annually from the consequences of venous thrombosis [2].
Limitations
Section titled “Limitations”Methodological and Statistical Constraints in Genetic Discovery
Section titled “Methodological and Statistical Constraints in Genetic Discovery”Early genome-wide association studies (GWAS) for venous thromboembolism (VTE) often involved relatively modest sample sizes, such as meta-analyses combining data from 1,953 cases and 2,338 controls[12]. While meta-analysis tools like METAL [13] improved power, these numbers can still be insufficient to detect genetic variants with small effect sizes, which are characteristic of complex diseases. This limitation may lead to an underestimation of the true genetic architecture of VTE and potentially inflate effect sizes for initially identified variants due to winner’s curse, making replication challenging in subsequent studies.
The multifactorial nature of VTE suggests that its genetic basis may involve more than single genetic variants, including complex gene-gene (SNP x SNP) interactions [12]. Identifying such interactions requires exceptionally large sample sizes and advanced statistical methods, which were not always feasible in earlier studies. Consequently, many potential synergistic or antagonistic genetic effects on VTE risk may remain undiscovered, limiting a comprehensive understanding of the disease’s genetic pathways.
Phenotypic Variability and Generalizability Across Populations
Section titled “Phenotypic Variability and Generalizability Across Populations”The definition and measurement of VTE phenotypes can vary across studies, potentially introducing heterogeneity that complicates meta-analyses and replication efforts. For instance, some studies have relied on self-reported VTE events [14], which, while useful for large cohorts, may be subject to misclassification or recall bias compared to clinically confirmed diagnoses. Given VTE’s classification as a “multifactorial disease”[2], precisely characterizing the specific type, severity, and recurrence of thrombotic events remains a challenge, impacting the ability to identify highly specific genetic associations.
A significant limitation of many genetic studies on VTE is their predominant focus on populations of European ancestry [15], [16]. While some studies have included other groups, such as South Asians [16], the lack of broad ancestral diversity restricts the generalizability of findings to global populations. Genetic risk factors and their effect sizes can vary considerably across different ancestral groups due to differences in allele frequencies, linkage disequilibrium patterns, and environmental exposures, meaning discoveries in one population may not translate directly to others.
Unaccounted Environmental Factors and the Missing Heritability
Section titled “Unaccounted Environmental Factors and the Missing Heritability”VTE is acknowledged to be influenced by both genetic and environmental determinants [1], and is widely considered a “multicausal disease”[17]. Factors such as obesity[1], age, and gender [4] are recognized as important physiological risk factors [18]. However, comprehensively accounting for these complex environmental factors and their interactions with genetic predispositions (gene-environment interactions) is challenging in study designs [3], potentially confounding genetic association signals or obscuring true underlying genetic effects.
Despite identifying numerous genetic loci associated with VTE, a substantial portion of its estimated heritability, approximately 30% [1], remains unexplained by common single nucleotide polymorphisms (SNPs)[19], [20]. This “missing heritability” could be attributed to several factors, including the contribution of rare variants, structural variations, epigenetic modifications, or unmeasured gene-gene and gene-environment interactions [1]. Consequently, current genetic models provide an incomplete picture of an individual’s total genetic risk for VTE [21].
Variants
Section titled “Variants”Genetic variations play a crucial role in an individual’s susceptibility to thromboembolism, a condition characterized by the formation of blood clots that can obstruct blood vessels. These variants often reside in genes involved in the intricate processes of blood coagulation, fibrinolysis, and vascular regulation. Understanding these genetic influences provides insights into the biological pathways underlying the disease and potential targets for prevention and treatment.
Several key variants within genes encoding core components of the coagulation cascade are associated with altered thromboembolic risk. The F2 gene, which produces prothrombin, a central protein in clot formation, harbors the variant rs1799963 , also known as prothrombin G20210A. This variant is linked to increased prothrombin levels, enhancing thrombin generation and elevating the risk of venous thromboembolism (VTE)[7]. Similarly, variants within the F11 gene, such as rs3756011 , rs56810541 , and the intronic rs2289252 (also affecting F11-AS1), are associated with VTE risk by influencing coagulation factor XI activity, which amplifies thrombin production[8]. The FGG gene, encoding the fibrinogen gamma chain, and the FGA-FGG locus, are also critical, with variants like rs2066864 and rs2066865 impacting fibrinogen levels or function, thereby affecting clot stability and overall VTE susceptibility [14].
Beyond the direct coagulation factors, other genetic loci modulate thrombotic risk through diverse mechanisms. The ABO gene, which determines blood group, contains variants like rs115478735 and rs8176722 . Non-O blood types, influenced by these variants, are consistently associated with a higher risk of VTE due to elevated levels of von Willebrand Factor and Factor VIII, both pro-coagulant proteins [7]. The PROCR gene, found in the EDEM2-PROCR region, codes for the endothelial protein C receptor (EPCR), a key component of the anticoagulant protein C pathway. Variants such as rs2378335 can influence EPCR expression or function, potentially impairing protein C activation and leading to a prothrombotic state [14]. Additionally, genetic variants in ATP1B1, such as rs145163454 , have been linked to VTE risk, though its precise mechanism may involve indirect effects on endothelial cell function, inflammation, or vascular integrity [7].
Novel genetic associations continue to expand our understanding of thromboembolism.TSPAN15, which encodes tetraspanin 15, is a recently identified susceptibility locus for VTE [22]. The intronic variant rs17490626 in TSPAN15 is in strong linkage disequilibrium with rs78707713 , a lead VTE-associated SNP, suggesting it may influence gene expression or regulation by mapping to an enhancer domain [22]. Given that other tetraspanin family members are involved in hemostasis, TSPAN15 may contribute to VTE through novel biological pathways, such as regulating platelet function or von Willebrand factor release. The IWS1 gene, involved in transcription regulation, also contains variants like rs74492489 , which could potentially influence the expression of genes important for coagulation, fibrinolysis, or vascular health, thereby contributing to an individual’s overall thrombotic risk.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs145163454 | ATP1B1 | hemorrhoid thromboembolism thrombophilia blood coagulation disease deep vein thrombosis |
| rs115478735 rs8176722 | ABO | atrial fibrillation low density lipoprotein cholesterol measurement, lipid measurement low density lipoprotein cholesterol measurement low density lipoprotein cholesterol measurement, phospholipid amount cholesteryl ester measurement, intermediate density lipoprotein measurement |
| rs3756011 rs56810541 | F11 | protein measurement blood protein amount thromboembolism pulmonary embolism, Pulmonary Infarction heart disease |
| rs2289252 | F11, F11-AS1 | blood coagulation trait blood protein amount thromboembolism factor XI measurement protein measurement |
| rs1799963 | F2 | thromboembolism prothrombin amount deep vein thrombosis thrombin measurement drug use measurement, deep vein thrombosis |
| rs2066864 | FGG | thromboembolism deep vein thrombosis heart disease |
| rs2066865 | FGA - FGG | thromboembolism pulmonary embolism heart disease pulmonary embolism, Pulmonary Infarction encounter with health service |
| rs17490626 | TSPAN15 | thromboembolism interleukin-17 receptor A measurement proheparin-binding EGF-like growth factor amount platelet volume deep vein thrombosis |
| rs2378335 | EDEM2 - PROCR | drug use measurement, deep vein thrombosis deep vein thrombosis heart disease pulmonary embolism, Pulmonary Infarction thromboembolism |
| rs74492489 | IWS1 | pulmonary embolism, Pulmonary Infarction deep vein thrombosis thromboembolism heart disease |
Definition and Core Terminology of Thromboembolism
Section titled “Definition and Core Terminology of Thromboembolism”Thromboembolism refers to the obstruction of a blood vessel by a blood clot that has dislodged from another site in the circulation. Specifically, Venous Thromboembolism (VTE) is a complex and multifactorial disease that encompasses two primary clinical manifestations: deep vein thrombosis (DVT) and pulmonary embolism (PE)[1]. Venous thrombosis (VT), a precursor to VTE, is a common condition affecting approximately two individuals per thousand annually and is associated with a significant mortality rate, estimated at 10%[2]. The consequences of VT are substantial, with an estimated 25,000 deaths each year in England attributed to the disease[2].
Beyond acute events, VT carries a considerable burden of long-term morbidity. The recurrence risk of VT is approximately 6% per year, and about 25% of patients experience post-thrombotic disease within five years following an initial VT event[2]. The terminology highlights the dual nature of the condition: ‘thrombus’ refers to a stationary clot within a vessel, while ‘embolism’ denotes a clot that has traveled from its origin to occlude a distant vessel. VTE, therefore, represents the spectrum of disease where a thrombus forms in the venous system, often in the deep veins of the legs (DVT), and can then travel to the lungs, causing a PE[23].
Categorization and Etiological Frameworks
Section titled “Categorization and Etiological Frameworks”VTE is broadly categorized based on its etiology into secondary and idiopathic forms, reflecting the presence or absence of identifiable transient risk factors [24]. Secondary VTE is defined as an event occurring within three months following clear transient acquired risk factors, such as trauma, hospitalization, prolonged immobilization, or surgery, including the postoperative setting [24]. Additionally, VTE occurring in patients using oral contraceptives or hormone replacement therapy, or during pregnancy or the postpartum period, also falls under the secondary classification[24]. In contrast, idiopathic VTE refers to events that occur in the absence of any of these transient risk factors, indicating a less immediately apparent cause [24].
The conceptual framework for VTE posits it as a multifactorial disease, influenced by a combination of environmental and genetic determinants[17], [1]. The narrow-sense heritability of VTE has been estimated at approximately 30%, underscoring a significant genetic predisposition [1]. Key environmental and clinical risk factors include obesity (with genetically raised BMI associated with an increased risk), prevalent cancer, smoking, hypertension, diabetes mellitus, and hyperlipidemia[25], [26], [27]. The disease also demonstrates familial segregation, suggesting inherited susceptibility[5], [6].
Clinical Assessment and Diagnostic Modalities
Section titled “Clinical Assessment and Diagnostic Modalities”The diagnosis and management of VTE rely on a combination of clinical criteria and risk assessment tools. Clinical assessment involves evaluating the pretest probability of deep vein thrombosis, which is crucial for guiding subsequent diagnostic steps[28]. Standardized risk assessment models, such as those developed by Caprini, serve as guides for prevention and help identify individuals at higher risk for VTE events, particularly in surgical patients [29], [30], [31]. These tools integrate various clinical factors, including patient demographics and comorbidities, to stratify risk.
While direct diagnostic criteria for VTE typically involve imaging studies (e.g., ultrasound for DVT, CT pulmonary angiography for PE), the context of genetic and epidemiological studies often relies on well-defined phenotypic descriptions and classifications of reported events [14]. Biomarkers, such as those indicating inflammation, fibrinolytic, and prothrombotic states, are also studied in relation to VTE risk, particularly concerning factors like Body Mass Index, which can influence these markers[32]. The ongoing understanding of VTE recognizes its complexity, with evolving research continuing to refine diagnostic and risk stratification approaches.
Signs and Symptoms
Section titled “Signs and Symptoms”Clinical Manifestations and Disease Impact
Section titled “Clinical Manifestations and Disease Impact”Thromboembolism, particularly venous thromboembolism (VTE), manifests as a symptomatic condition with significant clinical consequences. It is recognized as a common multifactorial disease associated with a notable mortality rate, reported at 10%[2]. Beyond acute mortality, VTE carries a substantial risk of recurrence, estimated at approximately 6% per year[2].
The long-term impact of VTE extends to post-thrombotic disease, which develops in about 25% of patients within five years following an initial event[2]. In specific populations, such as children undergoing therapy for acute lymphoblastic leukemia (ALL), symptomatic VTE represents a critical complication that can lead to substantial morbidity, potential mortality, and the interruption or discontinuation of essential chemotherapy, consequently affecting survival outcomes[9].
Assessment of Risk and Contributing Factors
Section titled “Assessment of Risk and Contributing Factors”The clinical management of thromboembolism involves the assessment of pretest probability to guide diagnostic decisions[28], alongside risk assessment strategies to identify individuals predisposed to the condition [29]. While specific diagnostic biomarkers are not detailed, research indicates the relevance of biomarkers related to inflammation, fibrinolytic activity, and prothrombotic states in understanding disease risk, particularly in relation to factors like Body Mass Index (BMI)[10].
Objective measures often include clinical characteristics that show differences between VTE cases and controls, such as age, prevalence of cancer, smoking status, hypertension, diabetes mellitus, hyperlipidemia, and BMI[10]. Furthermore, patient-reported events are utilized in research frameworks to capture the occurrence of thrombosis [14], contributing to a broader understanding of presentation patterns and phenotypic diversity.
Heterogeneity and Prognostic Indicators
Section titled “Heterogeneity and Prognostic Indicators”The presentation of thromboembolism exhibits significant heterogeneity, influenced by inter-individual variation, age-related changes, and sex differences[4]. Studies have identified a major genetic susceptibility for venous thromboembolism in men[6], and genetic variations within pathways regulating anticoagulation, procoagulation, fibrinolysis, and innate immunity are recognized as risk factors [3]. This genetic component contributes to an estimated narrow-sense heritability of approximately 30% for VTE [1].
Environmental and acquired factors also contribute to this diversity, with conditions like obesity implicated as a causal risk factor[10]. Additionally, specific clinical contexts, such as malignancy, corticosteroid use, asparaginase therapy, immobilization, and the presence of central venous lines, significantly increase the risk and influence the presentation of VTE [9]. These diverse presentations and underlying risk factors underscore the importance of comprehensive assessment, as the disease is associated with considerable morbidity, recurrence risk, and long-term complications like post-thrombotic disease.
Causes of Thromboembolism
Section titled “Causes of Thromboembolism”Venous thromboembolism (VTE) is a complex and multifactorial disease, influenced by an intricate interplay of genetic predispositions and environmental factors . The disease presents a substantial economic burden and is associated with a recurrence risk of about 6% per year, with post-thrombotic disease developing in about 25% of patients within five years of an event[2]. The development of VTE is influenced by a combination of genetic predispositions and environmental factors [1].
The Multifactorial Nature of Venous Thromboembolism
Section titled “The Multifactorial Nature of Venous Thromboembolism”Venous thromboembolism arises from a complex interplay of inherited and acquired risk factors. While the narrow-sense heritability of VTE is estimated to be approximately 30%[1], numerous environmental and clinical factors significantly contribute to its onset [1]. Malignancy itself, along with specific treatment-related factors such as steroid use, asparaginase therapy, periods of immobilization, and the presence of central venous lines, are well-recognized contributors to an increased risk of VTE [9].
Obesity is also implicated as a causal risk factor for VTE, demonstrating how systemic physiological changes can heighten susceptibility[10]. Obesity influences the lipid profile and biomarkers of inflammation, contributing to a prothrombotic state and an altered fibrinolytic balance within the body[10]. These interactions highlight VTE as a disease where both intrinsic genetic makeup and extrinsic lifestyle or medical conditions converge to disrupt normal physiological processes.
Genetic Architecture and Susceptibility Loci
Section titled “Genetic Architecture and Susceptibility Loci”Genetic mechanisms play a crucial role in an individual’s susceptibility to VTE, with familial aggregation and twin studies demonstrating a major genetic component [18]. Genome-wide association studies (GWAS) have been instrumental in identifying numerous common susceptibility alleles and risk loci across the human genome [2]. Among the most consistently identified genetic factors are variations within the Factor V (FV) gene and the ABO blood group locus, both of which are strongly associated with VTE risk [33].
Further GWAS efforts have pinpointed additional risk variants in chromosomal regions such as 1q24.2 and 9q [7]. Specific genes like TSPAN15, SLC44A2, and ZFPM2 have also been identified as susceptibility loci for VTE [22]. These genetic variations can influence the function and regulation of critical proteins involved in anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways, ultimately contributing to an imbalance that favors clot formation [3]. The complex genetic landscape of VTE also suggests the involvement of gene-gene interactions that modulate overall risk [12], and studies have revealed genetic overlap between VTE and arterial vascular disease[1].
Core Molecular and Cellular Pathways
Section titled “Core Molecular and Cellular Pathways”The pathophysiology of VTE fundamentally involves a disruption of the delicate balance within the hemostatic system, which normally regulates blood clotting [34]. At the molecular level, this disruption manifests as an imbalance between procoagulant factors, which promote clot formation, and anticoagulant and fibrinolytic pathways, which prevent excessive clotting and break down existing clots [3]. Critical biomolecules involved include components of the coagulation cascade, such as Factor V, and key enzymes of the fibrinolytic system, like urokinase plasminogen activator and its inhibitor, plasminogen activator inhibitor-1 [35].
Beyond coagulation, inflammatory processes also contribute significantly to VTE pathophysiology. Cytokines such as Interleukin-6 (IL-6) play a crucial role, and its modulation is considered a potential therapeutic target for post-thrombotic syndrome, a common long-term complication of VTE [36]. Furthermore, elements of the innate immunity pathways are recognized as risk factors, highlighting the intricate cellular and molecular networks that govern the body’s response to injury and infection, and how their dysregulation can predispose to thrombotic events[3].
Tissue-Level Pathophysiology and Systemic Impact
Section titled “Tissue-Level Pathophysiology and Systemic Impact”Venous thromboembolism primarily involves the formation of thrombi within deep veins, most commonly in the lower extremities[2]. At the tissue level, the presence of a clot initiates a localized response, including vein wall remodeling, a process influenced by molecules such as urokinase plasminogen activator and plasminogen activator inhibitor-1 [35]. This remodeling can alter the structural integrity and function of the affected vein. The most severe systemic consequence of VTE is pulmonary embolism (PE), which occurs when a part of the venous clot detaches, travels through the bloodstream, and lodges in the pulmonary arteries, potentially leading to life-threatening respiratory and cardiovascular compromise[37].
Long-term complications at the tissue level include post-thrombotic syndrome, a chronic condition characterized by pain, swelling, and skin changes in the affected limb, underscoring the enduring impact of the initial thrombotic event on tissue health[2]. During the natural process of thrombus resolution, key biomolecules like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are found within resolving venous thrombi, suggesting their involvement in the healing and revascularization of the affected tissue [38]. These factors contribute to the complex tissue interactions and systemic consequences that define the course and impact of VTE.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Genetic Predisposition and Gene Expression Regulation
Section titled “Genetic Predisposition and Gene Expression Regulation”Genetic studies have identified several loci associated with venous thromboembolism (VTE) risk, highlighting the role of inherited factors in disease susceptibility. Variants within theZFPM2 gene, which encodes a zinc finger protein known to function as a transcription factor, are implicated in VTE, suggesting a role in regulating the expression of genes critical for vascular homeostasis. Similarly, TSPAN15 and SLC44A2 have been identified as susceptibility loci, with TSPAN15 encoding a tetraspanin protein involved in cell surface organization and signaling, and SLC44A2 encoding a choline transporter that can influence cellular functions relevant to thrombosis [22]. These genetic variations can lead to altered gene regulation, affecting the levels or function of proteins involved in coagulation, fibrinolysis, or vascular integrity, thereby predisposing individuals to a prothrombotic state.
Hemostatic Balance and Coagulation Cascade Modulation
Section titled “Hemostatic Balance and Coagulation Cascade Modulation”The delicate balance of hemostasis, involving both procoagulant and anticoagulant pathways, is a primary mechanism underlying thromboembolism. Genetic variants, such as single nucleotide polymorphisms (SNPs) within theABO blood group locus, significantly influence the circulating levels of key hemostatic proteins like Factor VIII and von Willebrand factor, thereby modulating an individual’s thrombotic risk [7]. Dysregulation of these hemostatic traits, often influenced by multiple genetic factors, can shift the system towards a prothrombotic state where excessive fibrin formation and impaired clot dissolution lead to VTE [34]. This imbalance represents a critical disease-relevant mechanism, where even minor alterations in the activity or concentration of coagulation factors can have significant functional consequences on blood clot formation and stability.
Metabolic Perturbations and Inflammatory Responses
Section titled “Metabolic Perturbations and Inflammatory Responses”Metabolic pathways play a crucial role in modulating the risk of thromboembolism, with obesity identified as a causal risk factor[25]. Obesity is associated with alterations in lipid profiles and an increase in biomarkers of inflammation, which together contribute to a fibrinolytic and prothrombotic state[25]. This metabolic dysregulation involves changes in energy metabolism and biosynthesis pathways that favor the production of pro-inflammatory mediators and factors that promote coagulation. The chronic inflammatory environment, driven by altered metabolic flux, further exacerbates the prothrombotic tendency by influencing endothelial function and platelet activation, representing a significant systems-level integration of metabolic and inflammatory signals in VTE pathogenesis.
Network Interactions and Systemic Integration
Section titled “Network Interactions and Systemic Integration”Thromboembolism arises from a complex interplay of multiple pathways rather than isolated genetic effects, demonstrating significant systems-level integration. Research has uncovered “SNP x SNP interactions,” where combinations of genetic variants, rather than individual ones, significantly modulate the risk of venous thrombosis, indicating intricate pathway crosstalk and network interactions[12]. Furthermore, multi-phenotype analyses of hemostatic traits reveal how various genetic factors collectively influence the coagulation system, highlighting a hierarchical regulation that contributes to the emergent properties of thrombotic risk [34]. This integrated view also encompasses genetic overlap between venous and arterial vascular diseases, suggesting shared underlying mechanisms and broader systemic vulnerabilities that contribute to thrombotic disorders [1].
Clinical Relevance
Section titled “Clinical Relevance”Thromboembolism, particularly venous thromboembolism (VTE), is a prevalent multifactorial condition associated with significant morbidity and mortality, affecting approximately two individuals out of one thousand annually[2]. The clinical relevance of understanding this condition spans from accurate risk assessment and personalized prevention to effective long-term management and the recognition of associated comorbidities. Insights from large-scale genetic studies and clinical cohorts are continuously refining these aspects of patient care.
Risk Assessment, Stratification, and Prevention Strategies
Section titled “Risk Assessment, Stratification, and Prevention Strategies”Accurate risk assessment is fundamental in managing thromboembolism, guiding both diagnostic efforts and prophylactic interventions. Clinical tools such as the Wells score for deep-vein thrombosis and the Caprini risk assessment model are widely used to identify individuals at risk[39]. Complementing these clinical assessments, genetic insights play a crucial role in enhancing risk stratification, particularly given that the heritability of VTE is estimated to be approximately 30% and familial risks are well-documented [1].
Genome-wide association studies (GWAS) have advanced the field by identifying specific genetic susceptibility loci, including TSPAN15, SLC44A2, and ZFPM2, as well as risk variants in chromosomes 1q24.2 and 9q [22]. These genetic markers, alongside others, contribute to a more comprehensive understanding of an individual’s predisposition to thrombosis, with eight distinct loci associated with thrombosis identified in some studies [14]. Such genetic information enables personalized medicine approaches, particularly in high-risk populations like surgical patients, where genotype has been shown to influence postoperative VTE risk [39]. Integrating genetic data with traditional clinical risk factors allows for more precise identification of high-risk individuals and the implementation of tailored prevention strategies to reduce VTE incidence.
Prognosis, Recurrence, and Long-Term Implications
Section titled “Prognosis, Recurrence, and Long-Term Implications”Thromboembolism carries significant prognostic implications, with a reported mortality rate of approximately 10% and contributing to an estimated 25,000 deaths annually in England[2]. Beyond acute mortality, patients face a substantial risk of disease progression and recurrence, with about 6% experiencing a recurrent event each year[2]. A major long-term complication is post-thrombotic syndrome, which develops within five years in approximately 25% of patients, underscoring the chronic burden and substantial economic costs associated with the disease[2]. Pulmonary embolism, a severe manifestation of VTE, also contributes significantly to mortality rates[39].
Understanding the interplay between genetic and environmental factors is crucial for refining prognostic models and predicting long-term outcomes. While specific genetic markers for treatment response or monitoring strategies are not extensively detailed in the provided context, the identification of susceptibility loci implies their potential utility in predicting which patients are at higher risk for recurrence or the development of long-term complications like post-thrombotic syndrome. A comprehensive view of VTE’s natural history, informed by genetic insights, is essential for guiding ongoing patient management and improving quality of life.
Comorbidities and Associated Clinical Conditions
Section titled “Comorbidities and Associated Clinical Conditions”Thromboembolism frequently coexists with and is influenced by a range of significant comorbidities, highlighting the systemic nature of thrombotic risk. Obesity has been identified as a causal risk factor for VTE, with affected individuals exhibiting a higher average Body Mass Index compared to controls[10]. Furthermore, studies of VTE cases reveal higher rates of prevalent cancer, hypertension, diabetes mellitus, and hyperlipidemia compared to control populations[10]. These associations underscore a complex interplay between various chronic health conditions and an elevated risk for developing VTE.
Research has also uncovered a notable genetic overlap between venous thromboembolism and arterial vascular disease, suggesting shared underlying biological pathways that contribute to both conditions[1]. Multi-phenotype analyses of hemostatic traits have revealed novel genetic associations with cardiovascular events, further linking VTE with broader cardiovascular health[34]. For instance, elevated LDL cholesterol has been associated with an increased risk of VTE [1]. Recognizing these overlapping phenotypes and associated conditions is critical for a holistic approach to patient care, prompting clinicians to consider a wider spectrum of cardiovascular risk factors when managing individuals with thromboembolism.
Frequently Asked Questions About Thromboembolism
Section titled “Frequently Asked Questions About Thromboembolism”These questions address the most important and specific aspects of thromboembolism based on current genetic research.
1. My family has blood clots. Will I get them too?
Section titled “1. My family has blood clots. Will I get them too?”Yes, there’s a clear family link. About 30% of your risk for blood clots is inherited. If close relatives have had them, your personal risk is generally higher, indicating a genetic predisposition.
2. I’m pretty healthy, but my parents had clots. Can I still avoid them?
Section titled “2. I’m pretty healthy, but my parents had clots. Can I still avoid them?”Absolutely. While genetics contribute significantly, lifestyle choices and environmental factors also play a big role. Being healthy and managing other risk factors can help reduce your overall risk, even with a family history.
3. I’m trying to lose weight. Does my weight really affect my clot risk?
Section titled “3. I’m trying to lose weight. Does my weight really affect my clot risk?”Yes, it does. Research shows that obesity is directly implicated as a causal risk factor for developing blood clots. Managing your weight is a positive step to lower that risk.
4. I have a long flight coming up. Does sitting still increase my risk if clots run in my family?
Section titled “4. I have a long flight coming up. Does sitting still increase my risk if clots run in my family?”Yes, immobilization is a known risk factor for blood clots. If you have a genetic predisposition, prolonged sitting, like on a long flight, can increase that risk further.
5. My friend sits all day too, but I worry more. Is my clot risk different from theirs?
Section titled “5. My friend sits all day too, but I worry more. Is my clot risk different from theirs?”It could be. While lifestyle factors are important, about 30% of your risk for blood clots is inherited. So, even with similar habits, your unique genetic background might make your risk different from your friend’s.
6. Should I get a genetic test to see my blood clot risk?
Section titled “6. Should I get a genetic test to see my blood clot risk?”Genetic tests can identify specific markers associated with increased risk. However, blood clot formation is complex, involving many genes and environmental factors. A test might offer insights but won’t provide a complete picture of your individual risk.
7. If I’ve had a clot, does my genetics mean I’ll definitely get another one?
Section titled “7. If I’ve had a clot, does my genetics mean I’ll definitely get another one?”Not necessarily “definitely,” but having a previous clot increases your risk of recurrence, which is about 6% annually. Your genetic makeup can contribute to this ongoing risk, making it important to discuss prevention with your doctor.
8. Does my age or gender change my genetic risk for clots?
Section titled “8. Does my age or gender change my genetic risk for clots?”Yes, both age and gender can influence familial risks for blood clots. Studies have shown age- and gender-specific familial risks, with some research indicating a major genetic susceptibility in men, for example.
9. Why do some people get clots young, but others don’t until much later?
Section titled “9. Why do some people get clots young, but others don’t until much later?”Genetics can play a significant role in this difference. A stronger genetic predisposition might lead to developing blood clots at an earlier age, while others might be more influenced by accumulating environmental factors over time.
10. I have another health problem. Can genetics link it to my clot risk?
Section titled “10. I have another health problem. Can genetics link it to my clot risk?”Yes, there can be genetic connections. Studies have found genetic overlaps between the risk for blood clots and arterial vascular diseases. Certain health conditions like malignancy are also known risk factors that can interact with your genetic background.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Klarin D, et al. “Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.”Nat Genet, 2019.
[2] Germain M, Saut N, Greliche N, Dina C, Lambert JC, Perret C, Cohen W, Oudot-Mellakh T, Antoni G, Alessi MC, et al. “Genetics of venous thrombosis: insights from a new genome wide association study.” PLoS One, vol. 6, no. 9, 2011, p. e25581.
[3] Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, DE Andrade M. “Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism.”J Thromb Haemost, vol. 9, 2011, pp. 1133–1142.
[4] Zoller B, Li X, Sundquist J, Sundquist K. “Age- and gender-specific familial risks for venous thromboembolism: a nationwide epidemiological study based on hospitalizations in Sweden.”Circulation, vol. 124, 2011, pp. 1012–1020.
[5] Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, M DEA. “Familial segregation of venous thromboembolism.”J Thromb Haemost, vol. 2, 2004, pp. 731–736.
[6] Larsen TB, Sorensen HT, Skytthe A, Johnsen SP, Vaupel JW, et al. “Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins.”Epidemiology, vol. 14, 2003, pp. 328–332.
[7] Heit JA, et al. “A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q.”J Thromb Haemost, vol. 10, 2012, pp. 1521–1531.
[8] Tang, W., et al. “A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.”Genetic Epidemiology, 2013.
[9] Mateos, M. K., et al. “Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children.”Cancers (Basel), vol. 12, no. 5, 2020, p. 1297.
[10] Klarin D, et al. “Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.”Circ Cardiovasc Genet, 2017.
[11] Beckman, Marguerite G., et al. “Venous thromboembolism: a public health concern.”American Journal of Preventive Medicine, vol. 38, no. 4, 2010, pp. S495-S501.
[12] Greliche N, et al. “A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis.” BMC Med Genet, vol. 14, 2013, p. 36.
[13] Willer, C. J., et al. “METAL: fast and efficient meta-analysis of genomewide association scans.” Bioinformatics, vol. 26, no. 17, 2010, pp. 2190–91.
[14] Hinds DA, et al. “Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.” Hum Mol Genet, vol. 25, 2016, pp. 1867–1874.
[15] Benjamin, E. J., et al. “Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry.” Nat Genet, vol. 41, no. 8, 2009, pp. 879–81.
[16] Peden, J., et al. “A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.”Nat Genet, vol. 43, no. 4, 2011, pp. 334–41.
[17] Rosendaal FR. “Venous thrombosis: a multicausal disease.”Lancet, vol. 353, 1999, pp. 1167–1173.
[18] Souto, J. C., et al. “Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.” Am J Hum Genet, vol. 67, no. 6, 2000, pp. 1452–59.
[19] Manolio, T. A., et al. “Finding the missing heritability of complex diseases.” Nature, vol. 461, no. 7265, 2009, pp. 747–53.
[20] Eichler, E. E., et al. “Missing heritability and strategies for finding the underlying causes of complex disease.”Nat Rev Genet, vol. 11, no. 6, 2011, pp. 446–50.
[21] So, H. C., et al. “Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases.” Genet Epidemiol, vol. 35, no. 4, 2011, pp. 310–17.
[22] Germain M, et al. “Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.”Am J Hum Genet, 2015.
[23] Horlander, K. T., et al. “Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data.”Arch. Intern. Med., vol. 163, no. 14, 2003, pp. 1711–1717.
[24] Heit, J. A., et al. “Identification of unique venous thromboembolism-susceptibility variants in African-Americans.”Thromb Haemost, vol. 117, no. 4, 2017, pp. 687–694.
[25] Klarin, D., et al. “Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.”Circ Cardiovasc Genet, vol. 11, no. 2, 2018, e001712.
[26] Severinsen, M. T., et al. “Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study.”Circulation, vol. 120, no. 19, 2009, pp. 1850–7.
[27] Klovaite, J., et al. “Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study.”J Intern Med, vol. 277, no. 5, 2015, pp. 573–84.
[28] Wells, P. S., et al. “Value of assessment of pretest probability of deep-vein thrombosis in clinical management.”Lancet, vol. 350, no. 9094, 1997, pp. 1795-1798.
[29] Caprini, J. A. “Risk assessment as a guide for the prevention of the many faces of venous thromboembolism.”Am J Surg, vol. 199, no. 1 Suppl, 2010, pp. S3-S10.
[30] Bahl, V., et al. “A validation study of a retrospective venous thromboembolism risk scoring.”Am. J. Surg., vol. 199, no. 1 Suppl, 2010, pp. S3–S10.
[31] Gangireddy, C., et al. “Risk factors and clinical impact of postoperative symptomatic venous thromboembolism.”J. Vasc. Surg., vol. 45, no. 2, 2007, pp. 335–341.
[32] Klarin, D., et al. “Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State.”J Atheroscler Thromb, vol. 22, no. 6, 2015, pp. 610–7.
[33] Tregouet, David A., et al. “Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach.” Blood, vol. 113, no. 21, 2009, pp. 5298-5303.
[34] Temprano-Sagrera, G., et al. “Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations.”Journal of Thrombosis and Haemostasis, 2022.
[35] Zhou, R., et al. “The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.”Journal of Vascular Surgery, vol. 56, no. 4, 2012, pp. 1089-1097.
[36] Wojcik, Barbara M., et al. “Interleukin-6: a potential target for post-thrombotic syndrome.” Annals of Vascular Surgery, vol. 25, no. 2, 2011, pp. 229-239.
[37] Hirsh, Jack, and John Hoak. “Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association.”Circulation, vol. 93, no. 12, 1996, pp. 2212-2245.
[38] Waltham, M., et al. “Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi.” Journal of Vascular Surgery, vol. 32, no. 5, 2000, pp. 988-996.
[39] Christensen, M. A., et al. “An assessment of the effect of the genotype on postoperative venous thromboembolism risk in 140,831 surgical patients.”Annals of Medicine and Surgery (London), 2021.